Redmile Group LLC Trims Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Redmile Group LLC reduced its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 45.5% in the 1st quarter, Holdings Channel.com reports. The firm owned 29,546 shares of the medical equipment provider’s stock after selling 24,712 shares during the quarter. Redmile Group LLC’s holdings in Intuitive Surgical were worth $11,792,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of ISRG. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its holdings in Intuitive Surgical by 0.3% in the 4th quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 8,899 shares of the medical equipment provider’s stock valued at $3,002,000 after purchasing an additional 27 shares during the last quarter. Advance Capital Management Inc. grew its stake in shares of Intuitive Surgical by 3.8% in the first quarter. Advance Capital Management Inc. now owns 740 shares of the medical equipment provider’s stock valued at $295,000 after buying an additional 27 shares in the last quarter. Perigon Wealth Management LLC raised its holdings in shares of Intuitive Surgical by 0.5% in the 1st quarter. Perigon Wealth Management LLC now owns 5,363 shares of the medical equipment provider’s stock valued at $2,140,000 after buying an additional 27 shares during the period. Sheaff Brock Investment Advisors LLC lifted its stake in Intuitive Surgical by 1.3% during the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 2,226 shares of the medical equipment provider’s stock worth $751,000 after acquiring an additional 29 shares in the last quarter. Finally, Sugarloaf Wealth Management LLC grew its position in Intuitive Surgical by 5.7% in the 1st quarter. Sugarloaf Wealth Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $213,000 after acquiring an additional 29 shares in the last quarter. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Price Performance

ISRG stock traded up $2.36 during midday trading on Monday, hitting $443.66. The stock had a trading volume of 1,120,437 shares, compared to its average volume of 1,558,931. The company’s 50-day moving average price is $428.69 and its 200 day moving average price is $399.37. The firm has a market cap of $157.65 billion, a PE ratio of 80.08, a price-to-earnings-growth ratio of 4.86 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $468.78.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, beating the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The firm had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same quarter last year, the firm posted $1.18 earnings per share. Intuitive Surgical’s revenue for the quarter was up 14.5% compared to the same quarter last year. As a group, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 5.22 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on ISRG shares. Morgan Stanley increased their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Truist Financial boosted their price target on shares of Intuitive Surgical from $450.00 to $515.00 and gave the stock a “buy” rating in a research note on Tuesday, July 16th. BTIG Research raised their target price on shares of Intuitive Surgical from $451.00 to $459.00 and gave the company a “buy” rating in a report on Monday, July 15th. Robert W. Baird raised their price target on Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research note on Friday, July 19th. Finally, Stifel Nicolaus upped their target price on shares of Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $438.74.

Insider Buying and Selling

In other Intuitive Surgical news, Director Craig H. Barratt sold 2,496 shares of the business’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $402.89, for a total transaction of $1,005,613.44. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Intuitive Surgical news, Director Craig H. Barratt sold 2,496 shares of the business’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $402.89, for a total value of $1,005,613.44. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Mark Brosius sold 175 shares of Intuitive Surgical stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $389.16, for a total value of $68,103.00. Following the sale, the senior vice president now directly owns 883 shares in the company, valued at $343,628.28. The disclosure for this sale can be found here. In the last three months, insiders sold 12,982 shares of company stock valued at $5,451,547. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.